Combination of clofazimine and imatinib for effective therapy of drug-resistant myeloid leukemia

US10576078B2 · kind B2 · utility

Assignee

• COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH · IN

Inventors

• Sabyasachi Sanyal · Sidhauli, IN
• Harish Kumar · Sidhauli, IN
• Naibedya Chattopadhyay · Lucknow, IN
• Ravishankar Ramachandran · Sidhauli, IN
• Arun Kumarv Trivedi · Sidhauli, IN
• Sonal Shree · Sidhauli, IN
• Anagha Ashok Gurjar · Sidhauli, IN
• Sourav Chattopadhyay · Sidhauli, IN
• Sapana Kushwaha · Sidhauli, IN
• Abhishek Kumar Singh · Lucknow, IN
• Shikha Dubey · Sidhauli, IN
• Kiran Lata · Sidhauli, IN
• Riyazuddin Mohammed · Sidhauli, IN
• Jiaur Rahaman Gayen · Sidhauli, IN
• Anil Kumar Tripathi · Sidhauli, IN

Key dates

• Filing date: Aug 30, 2018
• Grant date: Mar 3, 2020
• Expiry date: Aug 30, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to method of treating chronic myeloid leukemia (CML) or drug resistant CML comprising, administering to human being or any other mammal or animal in need thereof, a therapeutically effective amount of Clofazimine (CFZ) or its pharmaceutically acceptable derivative, analogue, salt or composition; or a combination of a therapeutically effective amount of Clofazimine (CFZ) or its pharmaceutically acceptable derivative, analogue, salt or composition with a tyrosine kinase inhibitor (TKI). The invention also provides the kit for treatment of CML or drug resistant CML.